Introduction
Retinoids are active against neuroblastoma both as differentiation inducers and as cytotoxic agents. The differentiation inducer 13-cis-retinoic acid (13-cis-RA) achieved complete responses in a high-risk neuroblastoma phase I study of high-dose (2 weeks on, 2 weeks off) after myeloablative therapy (1) , and a randomized phase III study demonstrated that maintenance therapy of high-risk neuroblastoma with 13-cis-RA after completion of cytotoxic consolidation therapy significantly enhanced event-free survival (2) . Outcome in a subsequent nonrandomized study employing 13-cis-RA as maintenance therapy was consistent with a benefit from 13-cis-RA maintenance therapy (3) . A phase III trial demonstrated that maintenance therapy that combined 13-cis-RA with ch14. 18 antibody + cytokines further improved outcome (4).
The synthetic retinoid N-(4-hydroxyphenyl)retinamide (fenretinide; 4-HPR)
is cytotoxic for neuroblastoma in vitro by p53-independent and caspasedependent and -independent mechanisms that involve increases of reactive oxygen species (ROS) and dihydroceramides (5, 6) . Clinical activity in recurrent neuroblastoma of 4-HPR when given as sub-optimally bioavailable capsules was modest in early-phase studies (7) (8) (9) . Incorporation of 4-HPR into a lipid matrix (LYM-X-SORB™) and formulation as an oral powder (4-HPR/LXS) increased bioavailability and anti-neuroblastoma activity in mouse xenografts (10) . A pediatric phase I trial of 4-HPR/LXS demonstrated significantly higher 4-HPR exposures than previously achieved with the capsule formulation and documented four complete responses in recurrent neuroblastoma (11) .
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ABT-751 is a sulfonamide microtubule inhibitor that binds to the colchicine-binding site on beta-tubulin, inhibiting microtubule polymerization (12, 13) . In cell lines, exposure to ABT-751 leads to a cell cycle block at G2/M and induces apoptosis (13) . As ABT-751 is not a substrate for P-glycoprotein, it is active against tumor models resistant to other microtubule inhibitors, such as vincristine and paclitaxel, and ABT-751 has been shown to be active against neuroblastoma xenografts (14) . Phase I clinical trials with ABT-751 achieved stable disease but few objective responses in recurrent neuroblastoma (15) (16) (17) .
However, a Children's Oncology Group phase II study of ABT-751 failed to demonstrate an increase in progression-free survival when compared to historical controls (18) .
Although there has been a consistent improvement in outcome for neuroblastoma patients over the past 2 decades, many patients with high-risk neuroblastoma develop disease progression that is refractory to further therapy (19) . New drugs and drug combinations active against recurrent, multidrugresistant neuroblastoma are needed to improve survival. Moreover, welltolerated agents that demonstrate clinical activity against recurrent neuroblastoma may be used to further improve outcome by employing them in post-consolidation maintenance therapy (2, 4, 20) Both 4-HPR/LXS and ABT-751 are well-tolerated, orally available drugs with differing mechanisms of action and non-overlapping systemic toxicities that have shown single-agent activity in recurrent neuroblastoma preclinical models (5, 10, 14, 17) .
Thus, we investigated whether combining 4-HPR with ABT-751 could enhance anti-7 neuroblastoma activity against neuroblastoma cell lines and multidrug-resistant neuroblastoma xenografts established from patients with progressive disease. μg/mL transferrin, 5 ng/mL selenous acid, and 20% heat-inactivated FBS. Cell lines used in this study were tested to be Mycoplasma-free and maintained at 37°C in a humidified incubator containing 95% room air and 5% CO 2 atmosphere.
Materials and Methods

Chemicals
4-HPR and 4-HPR/LXS (the LYM
Cell line identities were validated at time of experimentation by short tandem repeat (STR) profiling (29) as compared to the Children's Oncology Group cell line and xenograft STR database (www.COGcell.org).
Cytotoxicity Assay
Cytotoxicity dose-response curves (4 days post start of drug exposure)
were determined using the DIMSCAN digital imaging microscopy assay system as previously described ((30, 31) . Concentration ranges tested in vitro (modeled on clinically obtainable plasma levels of active agents and taking into account protein-binding considerations) were:: 4-HPR, 0-10 µM; ABT-751, 0-500 ng/mL CLC, 0-10 µM; VCR, 0-10 µM; VRL, 0-10 µM; and PTX; vitamin C, 0-250 µM;
vitamin E, 0-250 µM; n-acetylcysteine 0-500 µM; sodium thiosulfate 0-500 µM.
Cells (4000 in 100 μL/well) were seeded in 96-well plates 16 to 24 hours before 100 μL of drugs (stock solutions: 10 mM 4-HPR in 99.5% ethanol; 1 mg/mL ABT-751 in DMSO) were added to each well (n = 12 replicates). For antioxidant studies, cells were pretreated for 3 hours with antioxidants before addition of 4-HPR and ABT-751. 
Determination of Reactive Oxygen Species Production
Assessment of Apoptosis In Vivo
When xenograft tumors measured 300 to 500 mm 
Results
Cytotoxicity of 4-HPR + ABT-751 in neuroblastoma cell Lines
We determined the cytotoxicity of 4-HPR, ABT-751, and fixed-ratio concentration combinations of both drugs, in nine human neuroblastoma cell lines using the DIMSCAN cytotoxicity assay. Dose-response curves to 4-HPR, ABT-751, and 4-HPR + ABT-751 in the neuroblastoma cell lines are shown in 4B. We repeated these this experiment using higher concentrations of NAC (.5 to 10 mM) and STS (.5 to 5 mM), which (unlike vitamins C and E) failed to decrease the cytotoxicity of 4-HPR + ABT-751 ( Supplementary Fig. S2 ). (Fig. 4C) . 
Effects of 4-HPR + ABT-
Antioxidants reduced apoptosis induced by 4-HPR + ABT-751 in neuroblastoma xenografts
We assessed apoptosis in SMS-KCNR xenografts from mice treated for 
Activity of various microtubule-targeting agents when combined with 4-
HPR.
We compared drug synergy between 4-HPR and five microtubule inhibitors (Fig. 6B) ; single-agent PTX (Fig. 6C) or CLC (Fig. 6D) 
Discussion
Through a series of early-phase and then randomized trials, intensive induction chemotherapy, local control with surgery and radiation, consolidation with myeloablative therapy, and post-consolidation maintenance therapy with 13-cis-retinoic acid + ch14.18 antibody + cytokines has been defined as the current optimal therapy for patients with high-risk neuroblastoma (2, 4, 19) . However, even with optimal therapy about one half of patients will develop progressive disease that is almost always less responsive to therapy than disease prior to progression and progressive disease on or after therapy is often fatal for high-risk neuroblastoma. Thus, there is a critical need for new drugs and novel drug combinations that are active against recurrent and refractory neuroblastoma.
In preclinical and clinical studies, the orally available colchicine binding site microtubule inhibitor, ABT-751, was well-tolerated and showed signals of activity against recurrent neuroblastoma (14) (15) (16) (17) , but in a neuroblastoma phase II clinical trial, ABT-751 achieved few objective responses and did not increase time-to-progression over historical controls (18) . Fenretinide also showed activity against recurrent neuroblastoma in preclinical studies (5, 6, 10) , signals of activity in early phase trials of a suboptimal capsule formulation (7) (8) (9) , and multiple complete responses in a phase I trial of a novel lipid matrix oral powder formulation (4-HPR/LXS) that increased 4-HPR exposures (11) . are capable of entering the mitochondria (39) (40) (41) , where the mitochondrial respiratory chain is a major source of intracellular ROS generation, as well as, an important target of ROS damage (42) . However, N-acetylcysteine and sodium thiosulfate, two thiol antioxidants that aid in the replenishment of glutathione (43, 44) , have not been shown to enter mitochondria. (8, 9, 11, 47) , that both 4-HPR/LXS and ABT-751 are well-tolerated as single agents (8, 9, 11, 15, 16, 18) , and that multiple complete responses in 
